以岭药业荣获2025【常春奖】年度中医药创新杰出企业

Group 1 - The core viewpoint of the article highlights that Yiling Pharmaceutical has been recognized as an outstanding innovative enterprise in traditional Chinese medicine at the 2025 Jiemian Finance Annual Conference, emphasizing its commitment to R&D innovation [1] - Yiling Pharmaceutical's R&D expenses reached 544 million yuan in the first three quarters of 2025, accounting for 9.27% of its operating revenue, indicating a strong focus on research and development [1] - The company has invested over 5 billion yuan in R&D from 2019 to 2024, maintaining a leading position in the industry [1] Group 2 - Yiling Pharmaceutical's innovative efforts have led to the approval and successful registration of its traditional Chinese medicine, Qifang Nasal Congestion Tablets, as the first registered innovative Chinese medicine in Macau [1] - The company has launched 17 patented traditional Chinese medicines targeting major diseases such as cardiovascular, respiratory, and endocrine disorders, showcasing a diverse product portfolio [1] - Several new traditional Chinese medicines, including Qigui Lobotomy Tablets and Children's Lianhua Qinggan Granules, are in the application or clinical research stages, indicating a rich pipeline of R&D reserves [1][3]